验证数据展示
经过测试的应用
| Positive WB detected in | Jurkat cells, Raji cells, THP-1 cells, HL-60 cells, U-937 cells |
| Positive IP detected in | HL-60 cells |
| Positive IHC-Autostainer detected in | human breast cancer tissue, Human Tonsil |
| Positive IHC detected in | human tonsillitis tissue, human appendicitis tissue, human lymphoma tissue, human spleen tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human tonsillitis tissue, human appendicitis tissue |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC)-AUTOSTAINER | IHC-AUTOSTAINER : 1:150-1:600 |
| Immunohistochemistry (IHC) | IHC : 1:200-1:800 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
发表文章中的应用
| WB | See 14 publications below |
| IHC | See 3 publications below |
产品信息
80313-1-RR targets BCL2 in WB, IHC, IHC-Autostainer, IF-P, IP, ELISA applications and shows reactivity with human samples.
| 经测试应用 | WB, IHC, IHC-Autostainer, IF-P, IP, ELISA Application Description |
| 文献引用应用 | WB, IHC |
| 经测试反应性 | human |
| 文献引用反应性 | human |
| 免疫原 |
CatNo: Ag3508 Product name: Recombinant human BCL2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-239 aa of BC027258 Sequence: MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | B-cell CLL/lymphoma 2 |
| 别名 | BCL-2 |
| 计算分子量 | 26 kDa |
| 观测分子量 | 26 kDa |
| GenBank蛋白编号 | BC027258 |
| 基因名称 | BCL2 |
| Gene ID (NCBI) | 596 |
| RRID | AB_2918886 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Protein A purification |
| UNIPROT ID | P10415 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
BCL2 belongs to the Bcl-2 family. It suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. BCL2 regulates cell death by controlling the mitochondrial membrane permeability (PMID: 10365962). It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PMID: 10444588).
实验方案
| Product Specific Protocols | |
|---|---|
| IF protocol for BCL2 antibody 80313-1-RR | Download protocol |
| IHC protocol for BCL2 antibody 80313-1-RR | Download protocol |
| IP protocol for BCL2 antibody 80313-1-RR | Download protocol |
| WB protocol for BCL2 antibody 80313-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Cell Death Dis TRIM25 degrades BRD7 protein stability through the ubiquitin proteasome pathway to promote breast cancer progression and paclitaxel resistance by activating YB1/Bcl-2 transcription axis. | ||
J Pharm Anal Rapid discovery of a novel "green" and natural GST inhibitor for sensitizing hepatocellular carcinoma to Cisplatin by visual screening strategy. | ||
Mater Today Bio Mitochondria-targeted phototherapeutic system enabling spatiotemporal-controlled NADH depletion for keloid intervention. | ||
Acta Biomater Bioactive Glass-Induced B Cell Depletion Remodels the Osteoimmunological Microenvironment to Enhance Osteogenesis | ||
Clin Transl Med Targeting c-Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple-negative breast cancer | ||
Chin Med Protective effects of Notoginsenoside R2 on reducing lipid accumulation and mitochondrial dysfunction in diabetic nephropathy through regulation of c-Src |
